Verve Therapeutics(US:VERV) Globenewswireยท2025-05-14 11:00Core Insights - Verve Therapeutics reported positive initial data from the Heart-2 Phase 1b clinical trial of VERVE-102, showing a mean reduction in LDL-C of 53% and a maximum reduction of 69% after a single infusion [1][2][3] - The company has a cash position of approximately $500 million, providing a runway into mid-2027 [1][2][8] - The Pulse-1 Phase 1b clinical trial of VERVE-201 targeting ANGPTL3 is ongoing, with updates expected in the second half of 2025 [1][4][2] Clinical Trial Updates - VERVE-102 is designed to permanently turn off the PCSK9 gene in the liver, leading to durable reductions in LDL-C levels [3] - Initial data from the Heart-2 trial included 14 participants, with a favorable safety profile and no serious adverse events reported [3] - The trial demonstrated dose-dependent decreases in LDL-C and PCSK9 protein levels, with a mean reduction of 60% in PCSK9 protein among participants in the 0.6 mg/kg cohort [3] Financial Performance - Collaboration revenue for the first quarter of 2025 was $33 million, a significant increase from $5.7 million in the same quarter of 2024, primarily due to the termination of a research collaboration with Vertex Pharmaceuticals [9] - Research and development expenses were $54.5 million for Q1 2025, compared to $48.4 million in Q1 2024 [10] - The net loss for the first quarter of 2025 was $31 million, or $0.35 per share, an improvement from a net loss of $48.7 million, or $0.59 per share, in Q1 2024 [12][18] Upcoming Developments - The company plans to dose the first patient in the Phase 2 clinical trial of VERVE-102 in the second half of 2025 [2][4] - Further updates on the Heart-2 trial and the VERVE-201 program are anticipated in the second half of 2025 [2][4] - Verve is also advancing the VERVE-301 program, which targets Lp(a) levels, with preclinical studies ongoing [5][13]